drug · small molecule
doxorubicin
Phase 2updated 5mo agoby Sunstate Biosciences LLC🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 30 sources
- drugDoxil59 co-mentions · 30 sources
- drugDOXIL (LIPOSOMAL)59 co-mentions · 30 sources
- drugDoxorubicin Teva31 co-mentions · 31 sources
- drugFarmiblastina31 co-mentions · 31 sources
- drugdoxorubicin hydrochloride30 co-mentions · 30 sources
- drugCHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]1 co-mentions · 1 sources
- companyCity of Hope1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 64 investigational indications.
targets
DNA topoisomerase 2-alpha
all catalysts(0)
nothing on the calendar yet
Trials studying doxorubicin
- phase3Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
- phase2A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- phase2A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
- phase2Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
- phase2Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
- phase3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- phase3A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
News(6)
- ‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrenceA standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.fiercebiotech · 2mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 4mo ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 5mo ago
- Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin LymphomaAlex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.onclive · 5mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 5mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 5mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that